Comparison of post-authorisation measures from regulatory authorities with additional evidence requirements from the HTA body in Germany – are additional data requirements by the Federal Joint Committee justified? by unknown
RESEARCH Open Access
Comparison of post-authorisation measures
from regulatory authorities with additional
evidence requirements from the HTA body
in Germany – are additional data
requirements by the Federal Joint
Committee justified?
Jörg Ruof1,2*, Thomas Staab1, Charalabos-Markos Dintsios3, Jakob Schröter4 and Friedrich Wilhelm Schwartz2
Abstract
Objectives: The aim of this study was to compare post-authorisation measures (PAMs) from the European Medicines
Agency (EMA) with data requests in fixed-termed conditional appraisals of early benefit assessments from the German
Federal Joint Committee (G-BA).
Methods: Medicinal products with completed benefit assessments during an assessment period of 3.5 years were
considered. PAMs extracted from European Public Assessment Reports (EPARs) were compared with data requests
issued by the G-BA in the context of conditional appraisals.
Results: Twenty conditional appraisals (19 products) and 34 EPARs containing PAMs (33 products) were identified.
Data categories (efficacy, safety, etc.), data types (type of study required to address the request) and clarity of requests
were determined. Conditional appraisals disproportionately focused on oncology products (13/19 products with
conditional appraisals vs. 14/33 products with PAMs). No clear rationale for the G-BA issuing conditional
appraisals could be identified in public sources. Both EMA and G-BA requested mainly efficacy and safety data
(44/54 and 23/35 categories requested, respectively); however, 28/35 G-BA data requirements went beyond
requests made by the EMA. Almost half of the G-BA requests (9/20), but no PAMs, were unclear, and no
methodological guidance for fulfilling the data requirements was provided by the G-BA.
Conclusions: Better alignment between data requests from regulatory authorities and health technology
assessment bodies is strongly recommended.
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Background
At the time of marketing authorisation, the available infor-
mation relating to a medicine may not yet be sufficient to
fully assess the benefit/risk profile to the desired degree of
certainty or may lack aspects of interests to the Committee
for Medicinal Products for Human Use (CHMP) that are
requested to be provided after marketing authorisation is
granted. Therefore, marketing authorisation agencies such
as the U.S. Food and Drug Administration (FDA) or the
European Medicines Agency (EMA) may require the
generation of additional data, e.g. in the form of clinical
studies.
The FDA refers to these additional requirements as
post-marketing requirements and commitments. These
gather additional information about a product's safety,
efficacy or optimal use [1]. The EMA can require post-
authorisation measures (PAMs) if the Agency’s commit-
tees consider the generation of additional data necessary
from a “public health perspective to complement the
available data with additional data about the safety and,
in certain cases, the efficacy of authorised medicinal
products”. Thus, like their FDA equivalent, PAMs are
mainly required in order to answer open questions re-
garding the risk/benefit profile or safety concerns of a
product [2].
The European Public Assessment Report (EPAR) pro-
vides details of the measures required for each product
and the agreed time frame for completion. PAMs are a
well-established component of the centralised proced-
ure for marketing authorisation in Europe and manu-
facturers are able to draw upon a wealth of guidance.
Generally, each PAM is discussed in detail by the EMA
and the manufacturer to define the clinical question and
the trial design, including details of the patient population,
intervention, comparison and outcomes of proposed stud-
ies [2]. PAMs are especially imposed on conditional mar-
keting authorisations or when marketing authorisations
have been granted under exceptional circumstances.
Since 2011, following the introduction of the Act for Re-
structuring the Pharmaceutical Market in Statutory Health
Insurance (Arzneimittel – Markt – Neu – Ordnungs –
Gesetz, AMNOG), a product has to undergo an early
benefit assessment after marketing authorisation and
launch in Germany. The assessment aims to determine
the additional benefit of a product against a pre-defined
appropriate comparator therapy in terms of morbidity,
mortality, quality of life and safety. The extent of add-
itional benefit granted will in turn influence the reim-
bursement price. Scientific information is presented by
the manufacturer in the form of a benefit dossier accord-
ing to a formalistic template and guidelines from the
Federal Joint Committee (Gemeinsamer Bundesausschuss,
G-BA). In general, the benefit assessment is conducted as
a two-step approach encompassing i) scientific assessment
by the Institute for Quality and Efficiency in Health Care
(IQWiG) and ii) appraisal by the G-BA; for orphan
drugs, both, assessment and appraisal, are performed
by the G-BA. A decision is made on the extent of the
additional benefit (major, considerable, minor, no bene-
fit or benefit less than comparator) and the level of
evidence (proof, indication, hint) [3–5]. Details of the
early benefit assessment procedure have been described
previously [6, 7].
Based on German social law, the G-BA has the option
to issue conditional appraisals [3, 5]. This is usually done
if no reliable conclusions regarding the extent of add-
itional benefit can be drawn from the submitted data [8].
After a pre-specified time frame, the G-BA will review
the additionally submitted scientific data and subsequently
re-assess a product’s additional benefit in a new proced-
ure. The G-BA’s decision rationale (Tragende Gründe)
provides further information on the requested data and
the time frame for submission of the updated dossier
containing the additional data [8]. In contrast to PAMs,
experience regarding conditional appraisals and add-
itional data requests by the G-BA is currently limited to
a 5-year time frame [8].
In this study, we compared the requests for additional
data by the EMA (PAMs) and the G-BA (conditional
appraisals) to illustrate differences in the categories and
types of requested data and to identify differences be-
tween PAMs and conditional appraisals in the still rather
new and developing early benefit assessment process in
Germany.
Methods
A step-wise approach was used for this analysis, com-
prising identification of all early benefit assessments of
new medicines or new indications during the first 3.5 years
after the introduction of the procedure in Germany, identi-
fication of the corresponding EPARs/EPAR variations and
subsequent classification of data requests in conditional
appraisals/PAMs. Parameters analysed included data cat-
egories, data types and clarity of data requests.
Identification and inclusion of benefit assessments
Benefit assessments conducted from 1 January 2011 (the
date of coming into effect of the new legislation) to 1 July
2014, excluding assessments of currently marketed phar-
maceuticals, and the respective appraisals were retrieved
from the G-BA website [8]. Conditional appraisals were
identified and the requested data were extracted from the
G-BA decision rationale [8]. For re-assessments of prod-
ucts for the same indication following additional data be-
ing filed by the manufacturer, only the latest assessment
was included.
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Identification and inclusion of EPARs and PAMs
PAMs and information on conditional approval or approval
under exceptional circumstances for the corresponding
products were obtained from the EPARs available on
the EMA website [9]. For each product, ongoing and
fulfilled PAMs were extracted from Annex II of the
EPAR and from the Procedural Steps, respectively. The
latest version of each document as of August 2014 was
used for each product. Products granted marketing au-
thorisation for an additional indication were counted
twice, as an EPAR variation report is available for the
new indication and PAMs can be clearly distinguished
between the two indications. Products not undergoing
the centralised procedure were excluded from the EPAR
analysis as no EPAR was available.
Classification of therapeutic indication
Therapeutic indications of products with conditional
appraisals or PAMs were classified as cardiovascular
disorders, infectious diseases, metabolic disorders, neuro-
logical disorders, oncology, ophthalmology, respiratory dis-
orders or others, according to the information on the G-BA
website [8].
Quality of data from RCTs for oncology drugs with
conditional vs. unconditional appraisals
For randomised controlled trials (RCTs) submitted by the
manufacturer for benefit assessments resulting in condi-
tional and unconditional appraisals in oncology, the follow-
ing parameters were analysed: number of RCTs, number of
patients in the largest trial, number of control arms, use of
an active control (extracted from the respective manufac-
turer’s dossier [8]), potential for bias (extracted either from
the respective IQWiG benefit assessment or the benefit
decision rationale of the G-BA [8]), availability of direct
comparison to appropriate comparator (extracted from
the respective benefit decision rationale of the G-BA [8]).
Categories of missing data
Data requests by the EMA and the G-BA were categorised
as efficacy, safety, effectiveness, pharmacology or reference
to EMA. A conditional appraisal or PAM could be in-
cluded in more than one category, but each category was
only counted once per appraisal or per product with
PAMs. Categories were defined as follows:
– Efficacy: efficacy data or specific efficacy
endpoint(s) explicitly mentioned in the EPAR or the
G-BA decision rationale and/or request listed in the
‘conclusions on clinical efficacy’ section of the
EPAR; data from (randomised) studies
– Safety: safety data or specific safety endpoint(s)
explicitly mentioned in the EPAR or the G-BA
decision rationale and/or request listed in the
‘conclusions on clinical safety’ section of the EPAR;
data from safety studies (randomised or observational
studies or registries)
– Effectiveness: data from non-interventional,
observational or 'real-life' studies or registries
other than for the purposes of safety monitoring,
or requests for data on representative patient
populations covering the entire indication
– Pharmacology: data on drug-drug interactions,
pharmacokinetics, pharmacodynamics, dosing or
dose timing
– Reference to EMA (only applicable for G-BA
requests): Data requests consistent with PAM(s)
Types of data requested
This assessment comprised the clarity of the request and,
for clear requests, the type of data requested. A request
was considered to be clear if the type of study required to
obtain the requested data was unambiguously specified
and either detailed guidance on e.g. endpoints was pro-
vided or protocol approval was required by the CHMP
prior to study start. Requests where these details were
missing were classified as unclear. Clarity was rated for
each individual PAM, but only once for each conditional
appraisal as a whole.
Types of data requests were categorised as follows:
– RCT: data from RCTs
– Non-RCT: data from non-randomised studies
– Analysis: new analyses of existing data or ongoing
studies
– Other: e.g. simulations or in vitro studies
– Reference to EMA (only applicable for G-BA
requests): data requests consistent with PAMs
Studies requested in the non-RCT category were further
subdivided into pharmacokinetic/drug interaction studies,
post-authorisation safety studies, single-arm studies, long-
term studies, registries, cohort studies or other, according
to the study description.
Main topics in G-BA data requests beyond EMA data
requirements
For conditional appraisals with G-BA data requests in
terms of efficacy, safety and effectiveness going beyond
EMA data requirements, the main topics of the requests
were identified and categorised as described below. Indi-
vidual requests could include more than one topic.
– Endpoint: Data on specific endpoints either not
presented by manufacturer or not accepted by
the G-BA
– Comparator: (Direct) comparison to the
appropriate G-BA-specified comparator missing
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– Long-term data: Data on long-term outcomes
missing
– Patient number: Number of patients for a specific
population too small
– Population: Further subdivision of population
requested
– Post-marketing safety concerns (specific to safety
requests): Safety concerns due to safety signals from
post-marketing experience
– Incomplete population (specific to effectiveness
requests): Study population not reflecting the
full indication
– Population not representative (specific to
effectiveness requests): Study population not
comparable to patients treated in the German context
Data extraction procedure
All assessments were conducted by two independent
reviewers to increase the level of objectivity in this




The analysis included 77 early benefit assessments con-
ducted during the 3.5-years assessment period and their
corresponding EPARs/EPAR variations where available.
An overview of the analysis set is shown in Fig. 1, and a
complete list of products with conditional appraisals
and/or PAMs can be found in Table 1.
The 77 benefit assessments covered 70 products as 7
products were assessed twice by the G-BA due to author-
isation for a new indication. Twenty appraisals (26 %),
covering 19 products, were conditional; for ipilimumab,
two conditional appraisals for two different indications
were included.
For 3 of the 70 products (extract of Cannabis sativa,
lisdexamfetamine dimesylate and pitavastatin), no EPAR
was available as they underwent a decentralised procedure.
Therefore, 67 products with 74 EPARs/EPAR variations
were included in the PAM analysis. Of these, 33 products
(49 %) had 34 EPARs with at least one PAM. Seven and 2
of the 33 products had obtained conditional approval and
approval under exceptional circumstances, respectively.
The total number of PAMs was 59, with 30 EPARs con-
taining only one or 2 PAMs (Table 1).
Therapeutic indications
An analysis of the therapeutic indications of products
with conditional appraisals (N = 19) and PAMs (N = 33)
revealed that oncology drugs comprised less than half of
the products (n = 14) which had a PAM, but more than
two-thirds of the products (n = 13) for which a condi-
tional appraisal had been issued.
Quality of data from RCTs for oncology drugs
As a disproportionally high proportion of conditional
appraisals concerned oncology drugs as compared with
other indications, the trial design of RCTs presented by
the manufacturer was compared for the products with
conditional (N = 12) vs. unconditional appraisals (N = 9)
in oncology (Table 2). In general, no distinctive differences
were evident, except that RCTs in conditional vs. uncondi-
tional appraisals were more frequently considered to have
a high potential for bias (67 % vs. 11 %) and were more
frequently active controlled (67 % vs. 33 %).
Categories of missing data
A total of 35 and 54 data categories were assigned to the
conditional appraisals and PAMs, respectively (Table 3).
In line with EMA guidelines [2], main categories re-
quested by the EMA were efficacy and safety (22/54 for
Total analysis
67 products with 67 EPARs 
and 7 EPAR variations/ 
extentions
Total analysis
70 products with 
77 benefit assessments
















Fig. 1 Dataset used for the analysis of conditional appraisals and PAMs
* Ipilimumab received a license expansion that resulted in an EPAR variation and a second benefit assessment. EMA: European Medicines
Agency; EPAR: European Public Assessment Report; G-BA: Federal Joint Committee; PAM: post-authorisation measure
Ruof et al. Health Economics Review  (2016) 6:46 Page 4 of 11
Table 1 List of products with conditional appraisalsa and/or PAMsb





Aclidinium bromide Eklira Genuair/
Bretaris Genuair
COPD No - 1 n.a.
Afatinib Giotrif Non-small-cell lung carcinoma Yes 1 0 -
Afliberceptf Zaltrap Metastatic colorectal cancer No - 1 4
Afliberceptf Eylea Age-related macular degeneration No - 1 5
Aliskiren/amlopidine Rasilamlo Essential hypertension No - 2 1; n.a.
Axitinib Inlyta Renal cell carcinoma Yes 4 0 -
Belatacept Nulojix Renal transplantation Yes 3 0 -
Belimumab Benlysta Systemic lupus erythematodes No - 3 1.5; 8.5; 11.5
Boceprevir Victrelis Chronic hepatitis C No - 1 4.5
Bosutinibg,c Bosulif Chronic myeloid leukaemia Yes 5 2 1; 5.5
Brentuximab vedoting,c Adcetris Hodgkin lymphoma, anaplastic
large-cell lymphoma
No - 4 Annually;
3.5; 3.5; 6
Crizotinibc Xalkori Non-small-cell lung carcinoma Yes 2 2 1.5; 3.5
Dabrafenib Tafinlar Melanoma Yes 3.5 0 -
Elvitegravir/cobicistat/emtricitabine/
tenofovir disoproxil
Stribild HIV infection No - 1 0.5
Emtricitabine/rilpivirine/tenofovir
disoproxilh
Eviplera HIV infection No - 2 1; 2
Eribulin Halaven Breast cancer Yes 2 0 -
Extract of Cannabis sativa Sativex Multiple sclerosis Yes 3 No centralised procedure
Fampridinec Fampyra Multiple sclerosis No - 1 5.5
Fidaxomicin Dificlir Infection with clostridium No - 2 1.5; 1.5
Fingolimod Gilenya Multiple sclerosis Yes 3 1 9.5
Fluticasone furoate/vilanterol
trifenatate
Relvar Ellipta Asthma, COPD No - 2 2; 2.5
Indacaterol/glycopyrronium Ultibro Breezhaler,
Xoterna Breezhaler
COPD No - 1 5
Ipilimumabi Yervoy Melanoma (pre-treated) Yes 5 1 6
Ipilimumab (new indication)i Yervoy Melanoma (treatment-naïve) Yes 3.5 1 6
Ivacaftorg Kalydeco Cystic fibrosis No - 2 3.5; 5.5
Lixisenatide Lyxumia Diabetes mellitus type 2 No - 1 1.5
Lomitapidec Lojuxta Hypercholesterolaemia Yes 1 2 Annually; 6.5
Ocriplasmin Jetrea Vitreomacular traction Yes 5 0 -
Pertuzumab Perjeta Breast cancer Yes 5 2 3.5; 4.5
Pirfenidoneg Esbriet Idiopathic pulmonary fibrosis No - 1 6.5
Pixantronec Pixuvri Non-Hodgkin lymphoma No - 1 3
Pomalidomideg Imnovid Multiple myeloma No - 2 1; 7
Ponatinibg Iclusig Lymphoblastic leukaemia,
myeloid leukaemia
Yes 1 0 -
Regorafenib Stivarga Colorectal cancer Yes 1.5 5 0.2; 0.2;
1; 2; 7.5
Rilpivirineh Edurant HIV infection No - 2 1; 2
Ruxolitinibg Jakavi Chronic myeloproliferative disorders No - 2 Annually; 1
Saxagliptin/metformin Komboglyze Diabetes mellitus type 2 Yes 2 0 -
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both). Seven of 35 G-BA data requests were consistent
with requests in the corresponding PAMs. The remaining
28 of 35 G-BA requests comprised additional data on effi-
cacy (n = 13), safety (n = 10) or effectiveness (n = 5), i.e.
80 % of the G-BA data requirements went beyond requests
made by the EMA. In contrast, the G-BA did not request
pharmacology data, which was covered by 8 PAMs.
Types of data requested
Data requests were initially categorised as clear or unclear
in terms of the requested study design, endpoints, etc. Nine
of 20 conditional appraisals but none of the 59 PAMs were
considered unclear. Clear requests were further divided by
data type (Fig. 2). The EMA requested the generation of
new non-RCT data and new analyses of existing data or
already initiated studies in 24 and 17 of 59 PAMs, respect-
ively. Requests for non-RCT data comprised mostly
pharmacokinetics/drug interaction studies (n = 7), post-
authorisation safety studies (n = 5) and single-arm studies
(n = 4) (see Table 4 for a complete list).
Of the 11/20 conditional appraisals classified as clear,
most (7/20) were consistent with the respective PAMs.
The remaining requests concerned new analyses and new
RCT data (3/20 and 1/20, respectively). No non-RCT data
were requested in accordance with the G-BA Rules of Pro-
cedure, which stipulate that RCT data are preferred for
benefit assessments [5].
G-BA data requests beyond EMA data requirements
Assessment of a product’s efficacy and safety profile typic-
ally falls into the domain of the licensing authorities, e.g.
the EMA or the German national licensing authorities. As
a substantial number (n = 14) of conditional appraisals
contained requests for efficacy and safety data going be-
yond those made by the EMA, these were further analysed
to identify the main topics covered.
A summary of this analysis is presented in Table 5. Key
topics in efficacy (N= 18) and safety (N= 13) requests were
endpoints that were missing or not accepted by G-BA (n = 8
and n= 2, respectively), missing data against the appropriate
Table 1 List of products with conditional appraisalsa and/or PAMsb (Continued)
Tafamidis meglumineg,c Vyndaqel Amyloidosis No - 1 annually
Ticagrelor Brilique Acute coronary syndrome No - 1 2.5
Trastuzumab emtansine Kadcyla Breast cancer No - 3 1; 3; 3.5
Vandetanibj,c Caprelsa Thyroid neoplasms Yes 3 2 2; 4
Vemurafenib Zelboraf Melanoma Yes 1 1 2
Vismodegibc Erivedge Basal cell carcinoma Yes 2 2 1; 2
COPD chronic obstructive pulmonary disease, n.a. not available, EPAR European Public Assessment Report, PAM post-authorisation measure
aN = 19 (20 appraisals);
bN = 33 (34 EPARs);
cindicates conditional marketing authorisation (bosutinib, brentuximab vedotin, crizotinib, fampridine, pixantrone, vandetanib and vismodegib) or marketing
authorisation under exceptional circumstances (lomitapide, tafamidis meglumine)
dConditional appraisals are issued with a single time frame
eMore than one PAM per product is possible; time frames are issued per PAM
fAflibercept is marketed as Zaltrap for colorectal cancer and as Eylea for age-related macular degeneration (AMD) and central retinal vein occlusion (CRVO).
Therefore, 3 benefit assessments (one for each indication) and 2 EPARs (for Eylea and Zaltrap) are available for aflibercept. The PAM given in the Eylea EPAR refers
to AMD; Eylea for CRVO was therefore omitted from the table
gMedicinal products with orphan status
hFor emtricitabine/rilpivirine/tenofovir disoproxil and rilpivirine, the same PAM was requested and was counted twice
iIpilimumab received a license expansion that resulted in an EPAR variation and a second benefit assessment. It had one PAM that was considered applicable to
both indications and was therefore counted twice
jIn case of no additional benefit due to missing data, the manufacturer can apply for re-assessment and subsequently submit the missing data. This was done for
vandetanib, and only the second assessment (with conditional appraisal) was included







Number of RCTs presented in manufacturer’s dossier (mean ± SD) 1.3 ± 1.2 1.0 ± 0.5 1.2 ± 1.0
Number of patients in largest RCT (mean ± SD) 577 ± 207 939 ± 361 729 ± 329
Number of control arms (mean ± SD) 1.1 ± 0.3 1.0 ± 0 1.1 ± 0.2
Use of an active control (n, %) 8 (67 %) 3 (33 %) 11 (52 %)
Benefit outcome influenced by potential for bias 8 (67 %) 1 (11 %) 9 (43 %)
Direct comparison to appropriate comparator available 9 (75 %) 7 (78 %) 16 (76 %)
RCT randomised controlled trial, SD standard deviation
aExcluding orphan drugs
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comparator (n= 4 and n= 5, respectively) and missing long-
term data (n= 4 and n = 2, respectively). Post-marketing
safety concerns accounted for 2/13 safety requests; only a
minority of efficacy and safety requests concerned insuffi-
cient patient numbers (n = 1 for both) and inappropriate
study populations (n= 1 for both). All effectiveness requests
(N= 5) focused on study populations, which either did not
comprise all patients included in the indication (n= 3) or
were not considered representative for Germany (n = 2).
Discussion
In this analysis, we compared post-authorisation con-
straints from the EMA and the G-BA during the first
3.5 years after the introduction of early benefit assess-
ment in Germany.
A considerable number of data requests by the G-BA
went beyond those issued by the EMA (80 %), which
may appear surprising considering a court ruling from
the Federal Social Court stipulating that the G-BA may
not issue a judgment on the quality, efficacy or safety of
a drug that deviates from that of the licensing authorities
[10]. However, according to the G-BA, the therapeutic
benefit required for a drug to be reimbursable by the
German sick funds is not identical to the therapeutic
efficacy and the favourable benefit-risk ratio proven by
the marketing authorisation [11]. In line with this, the
Federal Social Court acknowledged that there may be
discrepancies between the evidence gathered from piv-
otal trials and the requirements concerning the use of a
drug in clinical practice [12].
In particular, the G-BA considers itself not bound by
decisions made by the licensing authorities regarding
appropriate comparator and patient-relevant endpoints
[13], two areas of special relevance in the determination
of additional benefit. Indeed, the majority of additional
requests for both efficacy and safety data specifically
concern these two topics, which have previously been
identified as aspects in which G-BA requirements sub-
stantially deviate from the EMA’s viewpoint [7, 14–16].
A recent evaluation of parallel scientific advice meetings
demonstrated that the level of disagreement between the
EMA and health technology assessment (HTA) bodies re-
garding the comparator and endpoints was 30 % and
12 %, respectively [17], indicating that the different remits







Frequency of requests (%)
Conditional appraisals Products with PAMs
* Reference to EMA only applicable for G-BA appraisals
Fig. 2 Data type requests by the G-BAa and the EMAb
EMA: European Medicines Agency; G-BA: Federal Joint Committee; PAM: post-authorisation measure; RCT: randomised controlled trial; a per appraisal
(N = 20); b per PAM (N = 59)
Table 3 Categories of missing data for conditional appraisalsa
and PAMs
Conditional appraisals
(N = 35 categories)
nb
PAMs







Reference to EMAc 7 –
PAM post-authorisation measure
a19 products with 20 conditional appraisals, 33 products with 34 EPARs
bNumber of data requests for each category. More than one category of data
request was permissible for each PAM or conditional appraisal, but each
category was only counted once for each PAM or conditional appraisal
cReference to EMA only applicable for G-BA restrictions. All other G-BA data
requests (efficacy, safety, effectiveness and pharmacology) were unique to the
respective appraisals and were not reflected by EMA requests
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and perspectives of regulators and HTA bodies frequently
cause discrepancies regarding these points.
While the practice of issuing conditional appraisals
and requesting additional data has a clear legal basis and
is not questioned per se, this analysis identifies key short-
comings in the current G-BA approach such as a lack of
rationale for conditional appraisals, a lack of methodo-
logical guidance from the G-BA and a lack of flexibility
and pragmatism within the G-BA.
Our results demonstrate that the reasons for issuing
conditional appraisals are not transparent as the quality
of the submitted data for oncology assessments was over-
all comparable between conditional vs. unconditional ap-
praisals, except for minor deviations in the potential for
bias. In line with this, an analysis of G-BA appraisals
concerning products approved under special regulatory
circumstances showed that clear reasons for issuing
conditional or unconditional appraisals were not always
reported in the documentation of the assessment pro-
cedure [18].
Data requests by the G-BA are issued without any
methodological guidance to assist the manufacturer in
generating acceptable data [8]. In contrast, the majority
of PAMs requesting additional studies stipulated that the
study protocol should be approved by the CHMP prior
to study start [9]. This ensures alignment between the
manufacturer and the EMA and enables the manufac-
turer to adequately address PAM requests.
Other European HTA bodies also provide guidance re-
garding their preferred methodology. The French author-
ity, the Haute Autorité de Santé, can request additional
data, which may require new studies, during its assessment
procedure. In order to make sure the agency’s require-
ments are met, a guidance document regarding general
methodological considerations has been published, and the
study protocol has to be submitted for evaluation prior to
the start of the study [19].
The re-assessment of benefit after the expiry of the
conditional appraisal for vemurafenib illustrates the con-
sequences of the absence of such guidance by the G-BA.
In its initial assessment, the G-BA had suggested a historic
comparison of dacarbazine vs. vemurafenib to allow an
evaluation of the differences in overall survival. Although
this was provided by the manufacturer in a revised dossier,
the G-BA concluded that it was obsolete for methodo-
logical reasons and the initially assigned additional benefit
rating was not changed [8].
Our analysis reveals obvious differences in data hand-
ling between G-BA and EMA, with the EMA showing
considerably more flexibility in terms of data acceptance,
which may explain why almost half of the products with
a conditional appraisal received no PAM. Of note, the
EMA frequently had similar concerns to the G-BA, but
took additional data into account to answer open ques-
tions. This is partly due to the consideration of studies
involving different comparators and studies in which the
therapy under assessment was not administered at the
approved dose; most importantly, however, the EMA is
not limited to RCTs in its evaluations. Whereas the G-BA
mainly follows the methodology laid down by the IQWiG,
which requests RCT data wherever feasible [20], the EMA
also uses sources such as non-clinical studies or even ex-
pert advice to put data from pivotal trials into context.
A similarly less restrictive approach explicitly accept-
ing non-RCT data is used by the UK National Institute
for Health and Clinical Excellence (NICE) for HTA [21];
in such cases, data adjustment by modelling and a critical
appraisal of uncertainty are required. Modelling is gener-
ally used to extrapolate data that do not fit ideal require-
ments, e.g. surrogate endpoints, a shorter than desired
study duration or a study population that is not represen-
tative of patients within the UK National Health Service
[22]. NICE therefore tries to make the most of the avail-
able data and to obtain at least limited information,
whereas the G-BA in most cases categorically rejects all
data that do not conform to the IQWiG’s standards and
does not take this information into account. As the
Table 5 Main topics of G-BA data requests beyond EMA data
requirementsa
Efficacy Safety Effectiveness
Endpoint [8] Comparator [5] Incomplete population [3]
Comparator [4] Endpoint [2] Population not
representative [2]
Long-term data [4] Long-term data [2]
Patient number [1] Post-marketing safety
concerns [2]
Population [1] Patient number [1]
Population [1]
EMA European Medicines Agency, G-BA Federal Joint Committee
Numbers in brackets indicate the number of conditional appraisals concerned;
more than one topic per category was possible for each appraisal
aPer appraisal (N = 14)
Table 4 Non-RCT data required by the EMA as PAMs (N = 24)
Type of non-RCT PAM n
Drug interaction and PK studies 7
Post-authorisation safety studies 5
Single-arm studies 4




EMA European Medicines Agency, PAM post-authorisation measure,
PK pharmacokinetics, RCT randomised controlled trial
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vemurafenib example shows, the rigid data requirements
of the G-BA, together with the lack of methodological
guidance, also represent a significant obstacle to obtaining
a superior benefit rating in a re-assessment, even if new
data are submitted.
For medicines with conditional appraisals, as the ini-
tially presented data have not been considered to be fully
conclusive by the G-BA, it can be expected that the
benefit rating is conservatively low. This will influence
initial reimbursement as under AMNOG, the price of a
medicine is in part determined by its benefit rating [23].
In contrast, an improved benefit rating after re-assessment
would result in new price negotiations and potentially in a
higher price. Considering that the goal of AMNOG is to
reduce the rapidly increasing drug costs to the statutory
health insurance by 2.2 billion Euro per year [24], it could
be hypothesised that this may not be the desired outcome
in the eyes of the G-BA and the German sick funds. In fact,
a potential political motivation regarding data evaluation,
namely in the determination of the appropriate comparator
by the G-BA, in order to contain costs has been suspected
before [25].
In a worst case scenario, a drug can actually receive a
worse benefit rating after re-assessment, which would
very likely further lower its price. This occurred in the
case of regorafenib [8], which was consequently taken
off the German market after the re-assessment because
the manufacturer was not willing to further reduce the
price [26]. It has already been noted that AMNOG has
decreased the traditionally high availability of innovative
drugs on the German market through opt-outs following
benefit assessments [27]; conditional appraisals and the
resulting re-assessments may well contribute to this.
A structured collaboration between the German national
licensing authorities and the G-BA, in the form of national
joint scientific advice, has recently been established [28].
While this is a positive development, it has already been
clarified that this dialogue “will not, cannot and is not
intended to” harmonise study requirements [29]. This will
continue to make it difficult for manufacturers to obtain
data acceptable to both the EMA and the G-BA in one sin-
gle study. The previously cited analysis of joint scientific
advice meetings [17] showed that in cases where the EMA
and HTA bodies did not agree on the comparator, the
suggested solution was most frequently an indirect
comparison. However, given the stringent methodo-
logical requirements in Germany, it will be challenging
to obtain an additional benefit on this basis: of the first
23 indirect comparisons submitted after the introduc-
tion of AMNOG, only one was formally accepted by
the IQWiG [25].
A genuine harmonisation of study requirements between
regulators and HTA bodies has repeatedly been called for,
not just in relation to the G-BA [30, 31] but for European
HTA in general [17, 32]. More flexibility in HTA will
be especially crucial as new methods for marketing au-
thorisation emerge [33]. Alignment of data requests be-
tween the stakeholders, both around the time of
authorisation and during a product’s life cycle, would
markedly simplify the process of data generation to an-
swer important questions concerning a given drug.
This analysis has some limitations. Firstly, when review-
ing the Procedural Steps, only PAMs clearly identified as
such were included. Therefore, studies originally conducted
as PAMs but not appropriately labelled may have been ex-
cluded from the analysis. However, as only products with
newly granted marketing authorisations were assessed, it
can be assumed that the majority of PAMs have not yet
been fulfilled, and therefore the number of PAMs not
included is probably negligible. Secondly, the dataset is
relatively small as only appraisals from the first 3.5 years
of AMNOG were analysed and the number of available
benefit assessments from this period is limited. Future
studies on larger datasets will be required to validate
the conclusions drawn from this analysis.
Conclusions
In conclusion, it would be helpful if the factual basis for
conditional appraisals could be clarified. Moreover, clear
instructions regarding the fulfilment of data requests, as
typically provided for PAMs, would be beneficial in pro-
viding direction to the manufacturer and subsequently
enabling the G-BA to make an informed decision on the
additional benefit of a new medicinal product. Ideally,
discussions between the licensing authorities, the G-BA
and manufacturers early in a product’s life cycle should
determine the extent and format of the required data
and the strategies to be used for their generation. Undoubt-
edly, everybody, from licensing authorities over HTA bodies
and payers to clinicians and patients would stand to benefit
from this scenario.
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